Fujifilm expand presence in gene therapy development & manufacturing

Trial to evaluate enfortumab vedotin & Keytruda in metastatic urothelial cancer
Credit: Shutterstock.com/ PolakPhoto

Fujifilm is investing 13 billion yen ($120m) to expand its gene therapy capabilities as the Japanese CDMO looks to expand its presence in this fast growing field.

The investment includes establishing additional dedicated gene therapy laboratories at the Fujifilm Diosynth Biotechnologies (FDB) College Station, Texas camp

The laboratories will total 6,000 sqm and will be operation in fall 2021, the company said.

Fujifilm has also announced that additional investments include expanding FDB’s the gene therapy cGMP capacity.

The site has been offering gene therapy fill finish services for both clinical and commercial products since early 2019. The first stage of the manufacturing expansion is expected to be completed and in operation by the spring of 2021.